

When patients ask about occasional constipation

## Go with a gold standard

**PEG laxatives like MiraLAX® (PEG-3350) recommended more frequently than docusate<sup>1</sup>**

### PEG— Grade A recommendation<sup>1\*</sup>

- Based on Level I evidence<sup>†</sup>

### Docusate— Grade C recommendation<sup>1\*</sup>

- Based on Level III evidence<sup>†</sup>


## The weight of the clinical evidence is with MiraLAX

### PEG:

**22** studies with a mean of >100 participants up to 6 months treatment duration<sup>2-23</sup>

### Docusate:

**8** studies with a mean of <65 participants up to 4 weeks treatment duration<sup>24-31</sup>



**Start with MiraLAX®**  
**#1 GI-recommended OTC laxative**



GI=gastroenterologist; OTC=over-the-counter; PEG=polyethylene glycol.

\*Grade A=good evidence in support of the use of a modality in the treatment of constipation; Grade C=poor evidence to support a recommendation for or against the use of a modality.

<sup>†</sup>Level I=consistent results from well-designed, well-conducted studies; Level III=insufficient evidence due to limited number or power of studies and/or flaws in their design or conduct.

# PEG: A first-line recommendation across constipation guidelines

- Constipation management guidelines from multiple professional organizations recommend PEG as a first-line treatment
- Guidelines either don't mention docusate or don't recommend it prominently

## Recommendations

Source	Osmotic laxative (PEG)	Stool softener (docusate)
ASCRS 2016 <sup>32</sup>	Strong recommendation/ moderate-quality evidence	Insufficient evidence to warrant recommendation
AGA 2013 <sup>33</sup>	Strong recommendation/high-quality evidence	Not mentioned
ACG 2005 <sup>34</sup>	Strong recommendation/ moderate- to high-quality evidence	Insufficient evidence to warrant recommendation
ACG 2014 <sup>35</sup>	Strong recommendation/ high level of evidence	Not considered among interventions
Rome IV 2016 <sup>36</sup>	Included among therapeutic options for functional constipation	Not mentioned
AAFP 2015 (older adults) <sup>37</sup>	First-line recommendation after behavioral changes/evidence rating=A*	Second-line recommendation; no evidence rating offered

AAFP=American Academy of Family Physicians; ACG=American College of Gastroenterology; AGA=American Gastroenterological Association; ASCRS=American Society of Colon and Rectal Surgeons; Rome IV 2016=the Rome Foundation's 2016 publication in *Gastroenterology*.

\*Consistent, good-quality, patient-oriented evidence.

**References:** 1. Ramkumar D, Rao SSC. *Am J Gastroenterol*. 2005;100:936-971. 2. Bouhnik Y, et al. *Aliment Pharmacol Ther*. 2004;19:889-899. 3. DiPalma JA, et al. *Am J Gastroenterol*. 2007;102:1436-1441. 4. DiPalma JA, et al. *Am J Gastroenterol*. 2007;102:1964-1971. 5. Wang HJ, et al. *Drugs RD*. 2005;6:221-225. 6. Zangaglia R, et al. *Mov Disord*. 2007;22:1239-1244. 7. Chapman RW, et al. *Am J Gastroenterol*. 2013;108:1508-1515. 8. Cinca R, et al. *Aliment Pharmacol Ther*. 2013;37:876-886. 9. DiPalma JA, et al. *South Med J*. 2007;100:1085-1090. 10. Di Palma JA, et al. *Am J Gastroenterol*. 2000;95:446-450. 11. Cleveland MVb, et al. *South Med J*. 2001;94:478-481. 12. Chassade S, Minic M. *Aliment Pharmacol Ther*. 2003;17:165-172. 13. Attar A, et al. *Gut*. 1999;44:226-230. 14. Klauser AG, et al. *Z Gastroenterol*. 1995;33:5-8. 15. DiPalma JA, et al. *Online J Dig Health*. 1999;1:1-7. 16. Seinelä I, et al. *Drugs Aging*. 2009;26:703-713. 17. Awad RA, Camacho S. *Colorectal Dis*. 2010;12:1131-1138. 18. Andorsky RI, Goldner F. *Am J Gastroenterol*. 1990;85:261-265. 19. Corazziari E, et al. *Dig Dis Sci*. 1996;41:1636-1642. 20. Corazziari E, et al. *Gut*. 2000;46:522-526. 21. Freedman MD, et al. *J Clin Pharmacol*. 1997;37:904-907. 22. Brenner DM, et al. *Am J Gastroenterol*. 2019;114:954-963. 23. Migeon-Duballet I, et al. *Curr Med Res Opin*. 2006;22:1227-1235. 24. Tarumi Y, et al. *J Pain Symptom Manage*. 2013;45:2-13. 25. McRorie JW, et al. *Aliment Pharmacol Ther*. 1998;12:491-497. 26. Cass LJ, Frederik WS. *Am J Gastroenterol*. 1956;26:691-698. 27. Hyland CM, Foran JD. *Practitioner*. 1968;200:698-699. 28. Fain AM, et al. *South Med J*. 1978;71:677-680. 29. Castle SC, et al. *Geriatrics*. 1991;46:84-86. 30. Goodman J, et al. *J Chronic Dis*. 1976;29:59-63. 31. Chapman RW, et al. *Gastroenterology*. 1985;89:489-493. 32. Paquette IM, et al. *Dis Colon Rectum*. 2016;59:479-492. 33. Bharucha AE, et al. *Gastroenterology*. 2013;144:211-217. 34. American College of Gastroenterology Chronic Constipation Task Force. *Am J Gastroenterol*. 2005;100(suppl):S1-S22. 35. Ford AC, et al. *Am J Gastroenterol*. 2014;109(suppl):S2- S26; 36. Lacy BE, et al. *Gastroenterology*. 2016;150:1393-1407. 37. Mounsey A, et al. *Am Fam Physician*. 2015;92:500-504.

